Prnewswire Lipella Pharmaceuticals Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

FDA Grants Orphan Designation for Lipella s LP-310 Drug Candidate for Oral Graft-versus-Host Disease

Lipella Pharmaceuticals' LP-310 clinical stage asset is formulated for delivering active agents to the oral cavity for diseases of the mouth including oral lichen planus and oral graft-versus-host disease PITTSBURGH, Nov. 10, 2023 /PRNewswire/ Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical stage pharmaceutical company addressing serious diseases with significant unmet need based in Pittsburgh, PA, announced today that it has been granted "Orphan Drug Designation" from the U.S. Food

Prnewswire lipella pharmaceuticals incLipella pharmaceutical

Lipella Pharmaceuticals Announces Closing of $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Lipella Pharmaceuticals Announces Closing of $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesJonathan kaufmanJeff ramsonHc wainwright coLipella pharmaceuticals incLipella pharmaceuticalsPrnewswire lipella pharmaceuticals incExchange commissionSecurities act

Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-310 for Oral Lichen Planus

/PRNewswire/ Lipella Pharmaceuticals Inc. (Nasdaq: "LIPO") ("Lipella," "our, "us" or the "Company"), a clinical-stage biotechnology company addressing.

Jeff ramsonJonathan kaufmanLipella pharmaceuticalsScientific advisory board in oral healthPrnewswire lipella pharmaceuticals incDrug administrationLipella pharmaceuticals incInvestigational new drugScientific advisory boardOral healthMichael chancellorChief medical officerLichen planusLipella pharmaceuticals incHealth care amp hospitalsMedical pharmaceuticals

Lipella Pharmaceuticals Phase 2a Clinical Study Results Published in the Journal of Urology and Nephrology

Article highlights results from successful Phase 2a clinical trial for lead candidate, LP-10 Lipella expects to initiate Phase 2b clinical trial in LP-10 in early 2024 PITTSBURGH, Pa., Sept. 21,.

United statesJonathan kaufmanJason hafronChuck harbeyLipella pharmaceuticalsPrnewswire lipella pharmaceuticals incLipella pharmaceuticals incDrug administrationMichigan institute of urologyChief executive officerMichael chancellorChief medical officerOrphan disease designationMichigan institute

Lipella Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Update

/PRNewswire/ Lipella Pharmaceuticals Inc. (Nasdaq: "LIPO") ("Lipella," "our, "us" or the "Company"), a clinical-stage biotechnology company addressing.

United statesChuck harbeyJonathan kaufmanCook myositeExchange commissionCompany quarterly report on formMeeting of the american urological associationLipella pharmaceuticals incLipella pharmaceuticalsOral health scientific advisory boardPrnewswire lipella pharmaceuticals incAmerican urological association annual meetingHealth scientific advisory boardAmerican urological association annualInvestigational new drugAnnual meeting